Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab plus dexamethasone in heavily pretreated refractory or resistant multiple myeloma
2015-002221-19Phase 2Completed
- Sponsor
- CHU de Lille
- Start
- Aug 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of daratumumab and dexamethasone in multiple myeloma (MM), sponsored by CHU de Lille. Primary endpoint: Overall response rate. Started Aug 2015; status: completed.
02
Drugs
daratumumabdexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2015-002221-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002221-19.